PIN Pharma, Inc.

PIPELINE

PIN Pharma is focused on developing its lead compound, PIN-2, for immune modulation in cancer therapies with its first Phase 1 clinical study scheduled to finish in June of 2018. The study is designed to show clinically relevant increases in select immune markers in end stage patients with solid tumors.